The company's business model leverages recurring revenue streams and strong customer retention, supporting stable long-term growth. Key risks include potential regulatory changes and execution challenges that could impact future earnings. With FDA hurdles behind it and sales momentum building, Outset's Tablo is regaining traction across hospitals and ICU settings.
Outset Medical (OM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Outset Medical, Inc. (OM) came out with a quarterly loss of $3.24 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $8.55 per share a year ago.
The consensus price target hints at a 71.7% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The consensus price target hints at an 188.6% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Outset Medical (OM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
In 2025, Bitcoin (BTC -1.18%) has over-promised and under-delivered. After reaching $100,000 in December, Bitcoin looked like a no-brainer option to soar in value this year.
Outset Medical, Inc. (NASDAQ:OM ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call.
Outset Medical (OM 3.52%), the innovator behind the Tablo Hemodialysis System, reported fourth-quarter earnings on Wednesday, Feb. 19, that topped analysts' consensus expectations on top and bottom lines. Fourth-quarter revenue of $29.5 million exceeded the forecasted $28 million, indicating resilience in revenue growth despite market hurdles.
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.59 per share a year ago.
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical Inc. (NASDAQ:OM ) Q3 2024 Results Conference Call November 6, 2024 5:00 PM ET Company Participants James Mazzola - Head of Investor Relations Leslie Trigg - President, CEO & Chairman Nabeel Ahmed - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Avi Kohn RBC - Capital Markets Suraj Kalia - Oppenheimer & Co Marie Thibault - BTIG Josh Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the 2024 Third Quarter Outset Medical Conference Call.